AQSTAnother day, another lawsuit headline
Aquestive Therapeutics popped up in a shareholder alert from The Gross Law Firm, which says investors who bought AQST during the class period may be able to join a securities class action. In plain English: when a biotech trip gets messy, the lawyers start lining up like it’s opening night.
What’s the beef?
The notice points back to January 9, 2026, when Aquestive said the FDA had sent a letter flagging deficiencies that blocked labeling discussions for Anaphylm. The company also said the agency’s review was still ongoing, which effectively pushed any approval decision out past the January 31 PDUFA date.
Why investors should care
This isn’t just courtroom theater. Class actions can mean extra legal costs, more uncertainty, and a longer wait for any clean catalyst to show up. For a drug-development story, that’s basically the opposite of what shareholders want when they’re betting on a near-term approval win.
Big picture
The market usually hates two things more than one: delayed FDA decisions and lawsuit noise. Put them together, and you’ve got a stock that may stay volatile while everyone waits to see whether Anaphylm can still turn into a real commercial story.